Public Employees Retirement Association of Colorado Cuts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Public Employees Retirement Association of Colorado lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 11,779 shares of the company’s stock after selling 441 shares during the period. Public Employees Retirement Association of Colorado’s holdings in IDEXX Laboratories were worth $6,360,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of IDXX. Quent Capital LLC increased its stake in IDEXX Laboratories by 62.3% in the 4th quarter. Quent Capital LLC now owns 245 shares of the company’s stock worth $136,000 after buying an additional 94 shares in the last quarter. ICICI Prudential Asset Management Co Ltd boosted its holdings in shares of IDEXX Laboratories by 9.2% during the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 806 shares of the company’s stock valued at $447,000 after purchasing an additional 68 shares during the last quarter. Chicago Capital LLC boosted its holdings in shares of IDEXX Laboratories by 2.5% during the 4th quarter. Chicago Capital LLC now owns 93,963 shares of the company’s stock valued at $52,154,000 after purchasing an additional 2,276 shares during the last quarter. Waypoint Capital Advisors LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $222,000. Finally, Nvest Financial LLC boosted its holdings in shares of IDEXX Laboratories by 48.2% during the 4th quarter. Nvest Financial LLC now owns 1,607 shares of the company’s stock valued at $892,000 after purchasing an additional 523 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 0.2 %

NASDAQ IDXX traded up $0.95 during trading on Monday, hitting $470.66. The stock had a trading volume of 340,303 shares, compared to its average volume of 476,157. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The stock has a market capitalization of $38.87 billion, a price-to-earnings ratio of 45.38, a P/E/G ratio of 3.84 and a beta of 1.32. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a 50 day simple moving average of $493.61 and a 200 day simple moving average of $516.90.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Barclays lowered their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday. They issued a “buy” rating and a $580.00 price target for the company. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $585.89.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.